The Sunday Plenary will feature five scientific lectures that will focus on the influence of genetics on skin disease, tumescent drug delivery, how gene networks influence skin cancer, neurological causes of itch, and HIV/AIDS. It also will feature addresses by AAD President Mark Lebwohl, MD, and President-Elect Abel Torres, MD, JD, from 8 to 11:30 a.m. in Hall D.
Clarence S. Livingood,MD, Memorial Award and Lectureship
Genomics and other “-omics” are becoming increasingly available, and they are rapidly expanding our understanding of the underlying basis for inflammatory, neoplastic, and inherited skin disorders. This growing knowledge is leading to pathogenesis-based therapies — both gene-directed and pharmacologic — and is allowing us to track how intervention normalizes biological function.
During “Bedside to Bench and Back to Bedside,” Amy S. Paller, MS, MD, Walter J. Hamlin Professor and Chair of Dermatology and a professor of pediatrics at Northwestern University, Chicago, will highlight how decoding of the genetic, epigenetic, and transcriptomic features of common and rare skin diseases is defining new phenotypic classifications and beginning to shape practice.
“The future is bright for our patients in terms of the options they’ll have,” she said. “This is not just for the treatment of the unusual patient with a rare genetic disorder. The discoveries that are being made are going to be applied to a wide swath of our patients — even with common skin disorders. We need to be ready for and incorporate them into our practice.”
Eugene J. Van Scott Award for Innovative Therapy of the Skin and Phillip Frost Leadership Lecture
Tumescent lidocaine anesthesia (TLA) has been used as a local anesthetic in liposuction for 30 years, but Jeffrey A. Klein, MD, sees potential for its use in other surgical procedures and the delivery of new treatments for painful conditions.
Dr. Klein, a dermatologist from San Juan Capistrano, California, will discuss his self-funded research of TLA when he presents “Tumescent Drug Delivery: Lidocaine and Beyond.”
“I will talk about how we got to the current situation — the FDA-approved concentrations for lidocaine and how we got to the more liberal use of tumescent lidocaine anesthesia,” he said. “The potential new applications for tumescent drug delivery include tumescent antibiotic delivery for preventing surgical site infections and tumescent infiltration of acyclovir for treating Herpes zoster.”
Lila and Murray Gruber Memorial Cancer Research Award and Lectureship
Understanding all of the nuances of genetic research is a challenge, but when all of that research on skin cancers is put together, the message is clear: Sunlight is the major factor driving normal cells to mutate into skin cancer cells.
Paul A. Khavari, MD, PhD, professor and chairman of the department of dermatology at Stanford University School of Medicine, will explain sunlight-induced damage to the genome, especially in squamous cell carcinoma, when he presents “Pathogenesis of Skin Cancer.”
“The general principles of what we have learned in the field of cancer biology over the last three decades are now integrating with what we have been learning about skin cancer,” Dr. Khavari said. “An increasingly clear understanding is emerging of which genes are mutated by sunlight and how they cooperate to convert normal skin into cancer.”
Marion B. Sulzberger, MD, Memorial Award and Lectureship
Itch has long been associated with several dermatologic conditions, but it is also a disease all by itself. Gil Yosipovitch, MD, has studied itch for decades, and he has unique insights into its causes and treatments.
Dr. Yosipovitch, professor and chair of the department of dermatology and director of the Temple Itch Center at the Lewis Katz School of Medicine, Temple University, will present a lecture simply titled “Itch.”
“The idea of itch as a neuronal target is the major theme of my talk,” he said. “I will talk about the fundamental behavior of itch and scratch. All two- and four-legged animals scratch and itch. Chronic itch is a disease state.”
More than 1.2 million people in the United States are living with the HIV infection, according to the CDC. That number of new infections has stabilized at about 50,000 per year in recent years, and there are signs the virus may be under control.
Guest Speaker Anthony S. Fauci, MD, will discuss progress in controlling the disease when he presents “Ending the HIV/AIDS Pandemic: An Achievable Goal.” He is the director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
“I will not be talking about the dermatologic manifestations of HIV,” Dr. Fauci said. “I will talk about something that is somewhat historic, namely the fact that due to the investment in basic and clinical biomedical research related to HIV/AIDS, we have the tools to essentially end the HIV/AIDS pandemic as we know it in our lifetime.”
Watch for our complete coverage of the Plenary in Monday’s eDaily.